Bronchiectasis Therapeutic Market Trends

Growth Drivers

• Growing Awareness About the Disease - Market growth will be supported by an increase in global awareness of the disease. For example, to raise awareness about bronchiectasis, global lung health organizations from the USA, Europe, Australia, and Asia have joined together to declare July 1, 2022, as the first World Bronchiectasis Awareness Day, according to data published by the National Center for Biotechnology Information on July 1, 2022. The objective of the day is to raise awareness and increase knowledge about bronchiectasis worldwide, to effectively diagnose and manage this disease which has not been adequately addressed.
• Expansion of Biologics and Targeted Therapies - In the bronchiectasis drug market, biological products and targeted therapies are gaining attention. Specific molecules or pathways associated with the disease process are selectively targeted by these treatments. The potential for accurate and effective treatment is offered by biologicals like monoclonal antibodies and new small molecules. In patients with bronchiectasis, research continues to explore the use of targeted therapy for reducing inflammation, controlling infections, and improving lung function.

Challenges

• High Development Cost and Regulatory Obstructions - It may be costly and time-consuming to develop and market new bronchiectasis therapeutic. Pharmaceutical companies may find it difficult to access the market, due to a strict trial procedure, regulatory requirements, and difficulties in accessing the markets. Investment in R&D may be deterred by high development costs associated with the conduct of clinical studies and access to Regulatory Authorisations, which can limit innovation.
• Presence of Alternative Treatment Options is Set to hamper the market growth in the forecast period
• Complex Disease Pathophysiology is Expected to Hinder Market Expansion in the Upcoming Period.